Anna R Migliaccio, PhD Email Anna Migliaccio
- PROFESSOR | Medicine, Hematology and Medical Oncology
, Radiobiological Institute, TNO (Rijswiik, The Netherlands)
, University of Washington (Seattle, WA)
PhD, University of Naples (Naples, Italy)
PhD, University of Naples (Naples, Italy)
EnglishDownload the CV
International Journal Hematology
"Mouse models of Myelofibrosis"
The scope of this project is to exploit the Gata1low mouse model to detail the pathobiological pathway leading to development of increased stem/progenitor cell trafficking and extramedullary hematopoiesis in myleofibrosis
New York State Star Program:
"Personalized Therapies for Sickle Cell Disease and Thalassemia."
The scope of this project is to develop in vitro assays to predict the response to therapy with histone deacetylase inhibitors of sickle cell and thalassemia patients.
Member of the Program for Excellency in Training "Eurythron" European Community
The scope of this project is to establish a multicenter excellence training program in Experimental Hematology
Ghinassi B, Sanchez M, Martelli F, Amabile G, Vannucchi AM, Migliaccio M, Orkin SH, Migliaccio AR. The hypomorphic Gata1low mutation alters the proliferation/ differentiation potential of the common megakaryocytic-erythroid progenitor. Blood 2007; 109: 1460-1471.
Martelli F, Ghinassi B, Panetta B, Alfani E, Gatta V, Pancrazzi A, Bogani C, Vannucchi AM, Paoletti F, Migliaccio G, Migliaccio AR. Variegation of the phenotype induced by the GATA-1low mutation in mice of different genetic background. Blood 2005; 106: 4102-4113.
Vannucchi AM, Bianchi L, Paoletti F, Pancrazi A, Torre E, Nishikawa M, Zingariello M, Di Baldassarre A, Rana RA, Lorenzini R, Alfani E, Migliaccio G, Migliaccio AR. A patho-biological pathway linking thrombopoietin, GATA-1 and TGF-B1 in the development of myelofibrosis. Blood 2005; 105: 3493-3501.
Centurione L, Di Baldassarre A, Zingariello M, Bosco D, Gatta V, Rana RA, Langella V, Di Virgilio A, Vannucchi AM, Migliaccio AR. Increased and pathological emperipolesis of neutrophils within megakaryocytes associated with marrow fibrosis in GATA-1low mice. Blood 2004; 104: 3573-3579.
Migliaccio AR, Rana RA, Sanchez M, Lorenzini R, Migliaccio G, Orkin SH. GATA-1 as a regulator of mast cell differentiation revealed by the phenotype of the GATA-low mouse mutant. J Exp Med 2003; 197: 281-296.
Vannucchi A, Bianchi L, Cellai C, Paoletti F, Rana RA, Lorenzini R, Migliaccio G, Migliaccio AR. Development of myelofibrosis in mice genetically impaired for GATA-1 expression (Gata-1low mice). Blood 2002; 100: 1123-1132.
Migliaccio AR, Adamson JW, Stevens CE, Dobrila NL, Carrier CM, Rubinstein P. Cell dose and speed of engraftment in placental/umbilical cord blood transplantation: graft progenitor cell content is a better predictor than nucleated cell dose. Blood 2000; 96: 2717-2722.
Rubinstein P, Carrier C, Scaradavou A, Kurtzberg J, Adamson J, Migliaccio AR, Berkowitz RL, Cabbad M, Dobrilla L, Taylor P, Stevens C. Initial results of the placental/umbilical cord blood program for unrelated bone marrow reconstitution. New Engl J Med 1998; 339: 1565-1577.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Migliaccio did not report having any of the following types of financial relationships with industry during 2017 and/or 2018: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.